Monthly Archives: May 2012
Survival Data for Patients Younger Than 60 With Primary Myleofibrosis–Mayo Clinic Proceedings
Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years… Continue reading
Update on JAK Inhibitor — COMFORT II Trial interview with Claire Harrison, MD, at ASH 2011
At the American Society of Hematology (ASH) 2011, Claire Harrison, MD, discusses the updated analysis of the COMFORT II Study, which includes the significance of a 35% reduction in spleen volume in all subgroups. Also discussed are health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus… Continue reading
Survivor Interview Karen T.
Karen is a myelofibrosis survivor. She talks about managing graft versus host disease after receiving a bone marrow transplant, dealing with diabetes, and planning for her financial future.
A quote for you...
Powered By Optimism Quotes
MYELOFIBROSIS_1.swf
A personal patient documentary on his treatment for myelofibrosis
A quote for you...
Powered By Optimism Quotes
Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
Charles Hugh-Jones, MD, Vice President, Head of Medical Oncology Affairs, Sanofi North America, discusses the results of a phase I/II study looking at SAR302503, an investigational oral JAK2-selective inhibitor for patients with myelofibrosis. The trial enrolled 59 patients; 44 with primary myelofibrosis, 12 post-polycythemia vera, and 4 post-essential thrombocythemia. 86%… Continue reading
JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results
COMFORT-II, the second pivotal Phase III trial of the Janus kinase, or JAK inhibitor ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, or MF, when compared to best available therapy. The European study, called COMFORT-II showed treatment with ruxolitinib provided a statistically significant… Continue reading
Dr. Ruben Mesa Discusses the COMFORT Ruxolitinib Trials
Ruben A. Mesa, MD, Professor of Medicine, Chair, Division of Hematology & Medical Oncology, Mayo Clinic, Arizona, discusses the phase III Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) trials, which led to the FDA approval of ruxolitinib (Jakafi) for patients with myelofibrosis. COMFORT-I was a placebo controlled studied… Continue reading